Member Info for Peelweight

Hi Geovanni, I think Dr Mary is in phase 2 of a randomised controlled trial out of Amiens. Not certain but it looks like him, it is a RCT and it is still on the NIH website. Looks like they are trying to recruit 146 patients in France only (as per the NIH website, maybe only Amiens has started) and little COVID in France. He is looking to recruit hospital in-patients who require oxygen. Looks like a long road ahead? IMHO

https://clinicaltrials.gov/ct2/show/NCT04469491

Top effort Axe. Still here and getting increasingly "thirsty" for the party. Still happy to bring Malt Whiskers from the North

Peel

https://www.eurekalert.org/news-releases/932340

A2P3 progression, nice write-up

I don’t often quote Renton from Trainspotting but the full phrase used on waking to the RNS. Renton finds his beautiful, shining suppositories and exclaims “Yes, you f**king dancer!” as he rises up to the top.

Doc, cutting indeed. Verging on disrespectful to those that gave us the correct regime for dexamethasone use. Saying that, he has been provoked as we all know!

Sorry, wrong thread

TornadoTony, thanks for all your contributions. A tiny point, subcutaneous means under the skin. Intramuscular is the term for injections into a muscle

TornadoTony, thanks for all your contributions. A tiny point, subcutaneous means under the skin. Intramuscular is the term for injections into a muscle.

Fruits, quite right! I was sloppily using its trade name. Pedantry loss accepted
:-)

Hi Joeydiamond, my turn to apologise for being pedantic. The company is Regeneron, the active comparator for A2P3 is REGEN-COV. Cheers

Thanks Fruits and I do agree with you that many proof-of-concept hard yards have been taken in our HT that are directly relevant for post-hospital use, once a patient well enough to go home, if still on their 14-day course of SNG001. I hadn't considered that but the proof is there now from our HT certainly.

Matterhorn, I accept what you are saying also. If I put myself in the SNG PR dept trying to wrestle with a form of words to be positive about home treatment at this stage, it is difficult to find an acceptable phrase without stepping on NIAIDs toes. Maybe I have been reading too much in to it but was surprised about no mention at all in the RNS. We'll see

For me, this RNS confirms that 99% of the focus of SNG is on SPRINTER. The appointee was described and then commented solely on the upcoming P3 results.

We all hope that A2P3 will also come along and (much later) become valuable but the company have seen their own HT results, and all the A2 data and have decided not to mention home treatment at all in this RNS, nor have their new employee mention it. They are signalling the relative lack of importance of the A2 decision to corporate strategy and triple underscoring their confidence in SPRINTER P3, IMO

It’s going to be a long winter. Some comfort that still 90% effective in avoiding hospital admissions admissions.

RM indicated the A2 data was being analysed to decide on possible progression to A2P3, not we are trying to show our new production plans work and are safe, so we can progress to A2P3

I thought that was for the volume production solution for the 100K/month later, not for the odd 10s or 100s needed for SPRINTER and any A2P3 drug? I think we have stock in hand for the latter two. I could be wrong though.

Stu, the company is working with the A2 team reviewing the data and will decide with the A2 team once analysed. We are told this process is underway. Also, its Phase 3 of Active 2, not Active 3. Posters often refer to A2P3 for short, so as not to confuse with SPRINTER (also a P3)
Peel

I think it’s to be taken early, at diagnosis, for those at high risk. We won’t be in that market. If we are ever used pre-hospital, it will only ever be on those with marked or severe breathlessness.

Ah yes, I see now. He was politely thanking me for my reply

C'est moi

HelloSanDiego, I agree with you. Top line results are like the original announcement of our P2 results. If our top-line results are in any way similar to our P2 top line results, I think the EUA will be very shortly afterwards. Remember Synairgen is working on the EUA submission now, and will just drop in the last few percentage numbers with the top line results available. EUAs have been very quick in US with drugs of much worse efficacy. Albeit from US pharmas!